Metastasectomy for visceral and skeletal oligorecurrent prostate cancer
Tóm tắt
Metastasis direct therapy (MDT) is a common practice in different fields of oncology. However, there is a lack of data on surgical MDT in visceral/skeletal oligometastatic prostate cancer (PCa). We aimed to assess the role of surgical excision of visceral and skeletal PCa recurrence. Seventeen PCa patients experienced metachronous visceral or skeletal oligometastatic recurrence following maximal local treatment. Oligometastatic recurrence was defined as 1–3 lesions, detected with the best imaging technique available at the time of diagnosis. All patients underwent metastasectomy and were followed for a median of 43 months. Postoperative complications were graded using the Clavien–Dindo classification of surgical complications. Kaplan–Meier plots were used to assess overall survival. Fourteen patients (82%) had visceral lesions, two had bone lesions (12%), and one had an abdominal wall metastasis (6%). Four patients (24%) were under active ADT at the time of metastasectomy. PSA decreased after metastasectomy in 16 (94%) patients. Ten (77%) of the 13 ADT-naïve patients had a PSA decrease of ≥ 50%. Following metastasectomy, 16 (94.1%) patients developed metastatic recurrence of which 11 (64.7%) were again oligometastatic, amenable for repeated MDT. The median time to metastatic recurrence was 14 months (range 6.4–40). We observed 8% Clavien–Dindo grade 3–4 complications in 21 procedures. In this report, we analyzed the outcomes of surgical excision of visceral and skeletal PCa recurrence following primary treatment. We found that removing metastasis to the bone and viscera can be associated with long-term disease-free periods at a low rate of serious complications. These exploratory results should be confirmed in prospective studies.
Tài liệu tham khảo
Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW et al (2012) The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 102:32–39
Yossepowitch O, Bianco FJ, Eggener SE, Eastham JA, Scher HI, Scardino PT et al (2007) The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol 51(4):940–947 (discussion 947–948)
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642
Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T et al (2014) Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 12(9):135
Grubmüller B, Baltzer P, D’andrea D, Korn S, Haug AR, Hacker M et al (2018) 68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy—diagnostic performance and impact on therapeutic decision-making. Eur J Nucl Med Mol Imaging 45:235–242
Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N et al (2018) Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med 59:230–237
Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB et al (2003) Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61(3):607–611
Guler OC, Engels B, Onal C, Everaert H, Van den Begin R, Gevaert T et al (2018) The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients. Clin Transl Oncol 20(4):484–490
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453
Siva S, Bressel M, Murphy DG, Shaw M, Chander S, Violet J et al (2018) Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 74(4):455–462
Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G et al (2018) Novel insights into the management of oligometastatic prostate cancer: a comprehensive review. Eur Urol Oncol. https://doi.org/10.1016/j.euo.2018.09.005
Compérat E, Azzouzi A-R, Chartier-Kastler E, Ménégaux F, Capron F, Richard F et al (2007) Late recurrence of a prostatic adenocarcinoma as a solitary splenic metastasis. Urol Int 78(1):86–88
Ochoa C, Ramirez A, Varela R, Godoy F, Vargas R, Forero J et al (2017) Metastasectomy of abdominal wall lesions due to prostate cancer detected through PET/CT Gallium 68-PMSA: first Case report. Urol Case Rep 12:42–44
Kwon SY, Jung HS, Lee JG, Choi SH, Kwon TG, Kim T-H (2011) Solitary testicular metastasis of prostate cancer mimicking primary testicular cancer. Korean J Urol 52(10):718–720
Wallis CJD, English JC, Goldenberg SL (2011) The role of resection of pulmonary metastases from prostate cancer: a case report and literature review. Can Urol Assoc J 5(6):E104–E108
Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353–357
Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8–10
Weichselbaum RR (2018) The 46th David A. Karnofsky memorial award lecture: oligometastasis-from conception to treatment. J Clin Oncol 36:3240–3250 (JCO1800847)
Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel KA et al (2017) Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer 17(1):361
Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR (2013) Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2:215
Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N et al (2013) Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 11(1):27–32
Ouzaid I, Capitanio U, Staehler M, Wood CG, Leibovich BC, Ljungberg B et al (2018) Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol. https://doi.org/10.1016/j.euo.2018.08.028
Thomas AZ, Adibi M, Borregales LD, Wood CG, Karam JA (2015) Role of metastasectomy in metastatic renal cell carcinoma. Curr Opin Urol 25(5):381–389
Younes RN, Abrao F, Gross J (2013) Pulmonary metastasectomy for colorectal cancer: long-term survival and prognostic factors. Int J Surg 11(3):244–248